Molecular mechanisms underlying liposarcoma subtype transition and proteasome-associated targeted interventions Authors: Jiahao Liu, Mingke Huo, Sihan Wu, Zhen Wang, Sanfei Peng, Yang Fu Published: 2026 ABSTRACT BackgroundLiposarcoma (LPS) is one of the most common soft tissue sarcomas and is characterized by marked heterogeneity and a strong tendency toward recurrence. Conventional histopathologic classification mainly includes well-differentiated and dedifferentiated liposarcoma, myxoid and round cell liposarcoma, and pleomorphic liposarcoma. In recent years, molecular hallmarks, such as amplification of MDM2 and CDK4 and fusion genes including FUS::DDIT3 and CPSF6-related fusions, have become essential for accurate diagnosis and subtype assignment.Main bodyLPS development and subtype transition are driven by integrated molecular events, including 12q13–15 amplification with MDM2/CDK4 overexpression, PPARγ dysregulation, PI3K–AKT–mTOR activation, epigenetic alterations, and tumor microenvironment interactions. Together, these changes promote malignant transformation, dedifferentiation, and therapeutic heterogeneity across subtypes. Within this broader framework, the proteasome has emerged as a therapeutically relevant regulatory layer, particularly in selected contexts such as MDM2-amplified WDLS/DDLS, where protein turnover directly influences the stability of key driver proteins. Clinically, complete surgical resection remains the standard treatment when feasible, while doxorubicin plus ifosfamide is the mainstay for advanced or metastatic disease. Targeted therapies, such as palbociclib for MDM2-amplified WDLS/DDLS, as well as immunotherapy, have shown activity in some patients. Emerging investigational strategies also seek to target MDM2–p53, CDK4/6, epigenetic dysregulation, and proteostasis-related vulnerabilities.ConclusionThis review summarizes the classification, subtype-specific characteristics, molecular mechanisms, treatment strategies, and prognosis of LPS, and further discusses how proteasome-associated mechanisms may create therapeutic vulnerabilities in selected subtypes. A better understanding of the molecular basis underlying tumor initiation, progression, and subtype transition may support the development of more precise and mechanism-based therapeutic strategies for LPS. Introduction LPS is among the most common adult soft tissue sarcomas and comprises a group of mesenchymal malignancies with substantial heterogeneity arising from adipocytic precursors. LPS accounts for approximately 15% to 20% of all soft tissue sarcomas and preferentially occurs in deep soft tissues, most notably the retroperitoneum (approximately 40%–45%) and the extremities, particularly the proximal thigh (approximately 25%–30%). The median age at diagnosis is typically 50 to 60 years [1]. Clinical presentation is often insidious, especially in retroperitoneal disease, where tumors may reach very large sizes, frequently exceeding 15 cm and sometimes 20 cm, before causing compressive symptoms such as abdominal distension, pain, palpable mass, bowel or urinary obstruction, and lower extremity edema. Extremity LPS more commonly presents as a slowly enlarging, painless deep mass. Cross-sectional imaging with CT and MRI is central for assessing tumor location, size, extent, and relationships to adjacent structures. Classic well-differentiated lesions may contain abundant mature fat, whereas other subtypes often show more aggressive radiologic features [2]. Biologic behavior and prognosis are strongly subtype dependent. Based on the 2020 World Health Organization classification, LPS is commonly grouped into four major subtypes: well-differentiated liposarcoma (WDLS), dedifferentiated liposarcoma (DDLS), myxoid liposarcoma (MLS), and pleomorphic liposarcoma (PLS). This system reflects not only distinct histologic patterns but also closely aligned driver molecular features [3]. A detailed understanding of subtype-specific clinicopathologic traits, molecular foundations, evolutionary trajectories, and differential treatment responses is essential for precision management and improved outcomes. WDLS is the most common subtype and generally displays relatively indolent biology. Histologically, it consists of variably sized mature adipocytes with scattered atypical spindle or round stromal cells showing hyperchromatic nuclei, often separated by fibrous septa. The hallmark molecular event is amplification of the 12q13-15 region, resulting in overexpression of key oncogenes including MDM2, CDK4, and HMGA2. MDM2 amplification disrupts the p53 tumor suppressor pathway, while CDK4 amplification accelerates cell cycle progression [4]. WDLS typically grows slowly and recurs locally, particularly in the retroperitoneum, where wide margins are difficult to achieve. Ten-year cumulative local recurrence may reach 70% to 90%, whereas the risk of distant metastasis is low, under 5%. DDLS represents a step change in aggressiveness. It often arises from WDLS, either at presentation or upon recurrence, and contains a well-differentiated component plus an abruptly transitioning non-adipocytic dedifferentiated component, frequently resembling high-grade pleomorphic or undifferentiated sarcoma. DDLS retains 12q amplification but accumulates additional alterations, such as TP53 mutation or loss, CDKN2A loss, and amplifications involving 1p32 at JUN and 6q23 at MYB, among others, which collectively support dedifferentiation [5]. DDLS is associated with high local recurrence rates, roughly 40% to 80%, and higher distant metastasis rates, approximately 15% to 30%, commonly to the lung, liver, and bone, with substantially worse prognosis than WDLS. MLS is defined by a distinct molecular foundation, most commonly a t (12; 16) (q13; p11) generating the FUS::DDIT3 fusion gene, generating EWSR1::DDIT3. Histologically, MLS features relatively uniform primitive round to oval mesenchymal cells, abundant myxoid stroma, and a characteristic delicate branching capillary network. A crucial clinical and biologic issue in MLS is progression toward a higher-grade phenotype with an increased round cell component. When the round cell component exceeds 5%, aggressiveness increases markedly. Unlike dedifferentiation from WDLS to DDLS, this change reflects high-grade progression within the same fusion-defined MLS subtype. It is often associated with TP53 mutation or loss, PIK3CA mutation, PTEN loss, MYC amplification, and high Ki-67. MLS tends to metastasize to unusual sites, including the retroperitoneum, soft tissues, bone, and pleura [6]. PLS is the most aggressive subtype with the poorest outcomes. It is composed of highly atypical pleomorphic spindle and round cells and variable numbers of pleomorphic lipoblasts. Molecularly, PLS typically shows a highly complex karyotype without the subtype-specific alterations seen in WDLS, DDLS, or MLS, but frequently harbors TP53 mutation or loss and disruption of RB pathway control, including CDKN2A loss, RB1 inactivation, and CCND1 or CCND3 amplification, driving extreme genomic instability [7]. Tumors are often large and high grade at diagnosis, with both local recurrence and distant metastasis, predominantly to lung, and the lowest five year survival among LPS subtypes [3, 8] (Fig. 1). Fig. 1Representative imaging findings and gross specimens of major LPS subtypes. Computed tomography images in the top row and the corresponding surgical specimens in the bottom row illustrate the characteristic features of WDLS, DDLS, MLS, and PLS, highlighting their distinct radiologic appearance, macroscopic morphology, and marked clinicopathological heterogeneity across LPS subtypes. Abbreviations: CT, computed tomography; LPS, liposarcoma; WDLS, well-differentiated liposarcoma; DDLS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; PLS, pleomorphic liposarcoma Representative imaging findings and gross specimens of major LPS subtypes. Computed tomography images in the top row and the corresponding surgical specimens in the bottom row illustrate the characteristic features of WDLS, DDLS, MLS, and PLS, highlighting their distinct radiologic appearance, macroscopic morphology, and marked clinicopathological heterogeneity across LPS subtypes. Abbreviations: CT, computed tomography; LPS, liposarcoma; WDLS, well-differentiated liposarcoma; DDLS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; PLS, pleomorphic liposarcoma Malignant transformation in LPS includes biologically distinct processes, most notably dedifferentiation from WDLS to DDLS and high-grade progression in MLS with an increased round cell component, both of which are driven by multiple factors. In addition to the core genetic driver events above, such as the central role of TP53 inactivation in DDLS transition and the contribution of TP53 and PIK3CA alterations to round-cell transformation in MLS [9], epigenetic imbalance, such as hypermethylation of tumor suppressors including RASSF1A, HIC1, and CDKN2A and EZH2 mediated H3K27me3 silencing of differentiation genes, dysregulated signaling pathways, with PI3K–AKT–mTOR signaling playing a major role in progression across nearly all subtypes [10, 11], JAK-STAT activation by FUS::DDIT3 in MLS, and contributions of Wnt and Notch signaling in DDLS dedifferentiation [12], as well as tumor microenvironment remodeling, including infiltration of immunosuppressive M2 like tumor associated macrophages [13], activation of cancer associated fibroblasts that secrete pro tumor factors, extracellular matrix stiffening that activates YAP and TAZ signaling [14], and hypoxia induced HIF-1 alpha programs [15], all play indispensable roles. These mechanisms interact to confer proliferative advantages, evade apoptosis, suppress differentiation potential, enhance invasion and metastasis, and enable immune escape. Treatment strategies and prognosis are highly subtype dependent. Surgical resection aiming for R0 margins is the cornerstone for localized disease, but complete resection is particularly challenging for retroperitoneal DDLS. Radiotherapy is important for local control in extremity LPS, especially MLS. Chemotherapy, with doxorubicin and ifosfamide as first line and eribulin and trabectedin as second line, is effective for metastatic or unresectable LPS, but response rates differ markedly by subtype. MLS is relatively sensitive to trabectedin, whereas DDLS and PLS show poorer responses [16–19]. Targeted therapy is increasingly important: CDK4 and CDK6 inhibitors, including palbociclib and abemaciclib, are active in WDLS and DDLS, and MDM2 antagonists are in development. Immunotherapy shows limited overall activity in LPS, consistent with an immune cold phenotype. Prognosis varies: WDLS has long survival but frequent local recurrence; DDLS has poorer outcomes, and retroperitoneal location and TP53 or CDKN2A alterations are risk factors; MLS has intermediate outcomes overall but worsens after RCLS transition; PLS has the worst prognosis [20]. Notably, proteasome-related mechanisms may occupy an important position in LPS pathogenesis, with the strongest current evidence in WDLS and DDLS [21]. In these subtypes, MDM2, as an E3 ubiquitin ligase, drives excessive degradation of p53 through the ubiquitin proteasome system (UPS), linking a subtype-defining genomic alteration to protein turnover, stress adaptation, and tumor-cell survival. This supports the UPS as a biologically relevant and investigational therapeutic vulnerability in WDLS and DDLS. Preclinical studies suggest that proteasome inhibitors, such as bortezomib and carfilzomib, can stabilize p53 and induce apoptosis, providing a preclinical rationale for further translational evaluation rather than clinically validated therapy in LPS [22]. Although proteasome inhibitors have achieved major success in hematologic malignancies such as multiple myeloma, their clinical efficacy in solid tumors, including liposarcoma, has thus far remained limited. In recurrent or metastatic soft tissue sarcoma, single-agent bortezomib has shown minimal clinical activity, underscoring the gap between strong preclinical rationale and actual therapeutic benefit. Major barriers to translation include inadequate intratumoral drug delivery, tumor microenvironment-mediated protection, adaptive resistance mechanisms such as compensatory autophagy or proteasome remodeling, and dose-limiting toxicities. Current research therefore focuses on developing next-generation, more selective proteasome inhibitors, such as immunoproteasome inhibitors, and on rational combination strategies with CDK4/6 inhibitors, MDM2 antagonists, immune checkpoint blockade, and related approaches. This review first summarizes the subtype-specific molecular basis of malignant transition in LPS and then discusses how proteasome-associated mechanisms intersect with these processes and may create therapeutic opportunities in selected subtypes. Building on the subtype characteristics described above, understanding the key factors driving LPS initiation and malignant transition is critical for elucidating its biology [23]. The core determinants include genetic variation, epigenetic regulation, signaling pathway abnormalities, and tumor microenvironment effects, all interwoven (Fig. 2). Fig. 2Integrated framework of liposarcoma subtype transition and proteasome associated regulation. This figure summarizes the two major malignant transition routes in liposarcoma, namely dedifferentiation from well-differentiated liposarcoma to dedifferentiated liposarcoma and high-grade progression in myxoid liposarcoma with an increased round-cell component. It also shows how cumulative genomic alterations, epigenetic reprogramming, signaling rewiring, and microenvironmental stress interact with the ubiquitin-proteasome system during these processes. The key mechanistic message is that proteasome dependence in liposarcoma is context-dependent and is currently best supported in WDLS and DDLS. Abbreviations: LPS, liposarcoma; WDLS, well-differentiated liposarcoma; DDLS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; UPS, ubiquitin-proteasome system Integrated framework of liposarcoma subtype transition and proteasome associated regulation. This figure summarizes the two major malignant transition routes in liposarcoma, namely dedifferentiation from well-differentiated liposarcoma to dedifferentiated liposarcoma and high-grade progression in myxoid liposarcoma with an increased round-cell component. It also shows how cumulative genomic alterations, epigenetic reprogramming, signaling rewiring, and microenvironmental stress interact with the ubiquitin-proteasome system during these processes. The key mechanistic message is that proteasome dependence in liposarcoma is context-dependent and is currently best supported in WDLS and DDLS. Abbreviations: LPS, liposarcoma; WDLS, well-differentiated liposarcoma; DDLS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; UPS, ubiquitin-proteasome system In this review, subtype transition in LPS refers primarily to two biologically distinct processes: dedifferentiation from WDLS to DDLS and high-grade progression in MLS with an increased round cell component, both of which are driven by cumulative genomic alterations, epigenetic reprogramming, signaling rewiring, and microenvironmental stress. Within this context, we propose that the UPS acts as an integrative regulatory hub influencing subtype transition through coordinated control of protein stability and stress adaptation, most clearly in WDLS and DDLS, where MDM2 amplification directly promotes proteasome-mediated p53 degradation, but also through broader regulation involving E3 ligases, DUBs, the 26 S proteasome, ER stress/UPR signaling, compensatory autophagy, immunoproteasome-mediated antigen processing, and cell-cycle regulators such as p21 and p27. However, the strength of evidence is not uniform across these links, and several broader connections should presently be regarded as hypothesis-generating rather than established LPS-specific mechanisms. This framework therefore highlights the UPS as a context-dependent regulatory node linking oncogenic signaling, proteostasis control, and therapeutic vulnerability in LPS. Core genetic driver factors Genetic abnormalities form the foundation of LPS initiation and transition. Different subtypes harbor distinctive genetic alterations that directly drive the acquisition and evolution of malignant phenotypes. Amplification of the 12q13-15 region with MDM2 and CDK4 is the hallmark event of WDLS and DDLS [24–27]. This locus contains multiple key oncogenes. MDM2 encodes an E3 ubiquitin ligase and is the primary negative regulator of p53 [28, 29]. MDM2 amplification and overexpression inactivate p53 function, enabling cells to evade apoptosis and senescence and promoting genomic instability and tumorigenesis [30–32]. MDM2 amplification is detected in over 90% of WDLS and DDLS. CDK4 encodes cyclin-dependent kinase 4, and amplification leads to overexpression [33, 34], driving the G1/S cell-cycle transition and promoting aberrant cellular proliferation [35]. Co-amplification in this region often includes HMGA2, which participates in chromatin remodeling and embryonic development and may suppress differentiation [36], other co-amplified genes within the 12q13-15 amplicon [37–39], and DDIT3 [40, 41], collectively promoting tumorigenesis and progression. A key driver of dedifferentiation, the conversion of WDLS to DDLS, is that DDLS accumulates additional genetic alterations on top of the inherited 12q amplification, including amplification at 1p32 JUN, 1q21 MCL1, and 6q23 MAP3K5 (ASK1), and deletions in critical tumor suppressor regions, especially 17p13.1 TP53 loss [5, 42], Loss of TP53 function is considered a critical event that releases key constraints on genomic stability and cell-cycle control, thereby promoting dedifferentiation. In addition, alterations of CDKN2A (encoding p16INK4a), including deletion or mutation, are frequently observed in DDLS and further disrupt the RB signaling pathway [43]. FUS::DDIT3, or EWSR1::DDIT3, is the molecular foundation of MLS and round-cell transformation [44]. The t(12;16)(q13;p11) translocation produces the FUS::DDIT3 fusion protein, and a minority arise from t(12;22)(q13;q12) producing EWSR1-DDIT3. DDIT3, also known as CHOP, is a member of the C/EBP transcription factor family. The fusion protein acts as an aberrant transcriptional regulator. It disrupts adipocytic differentiation by strongly repressing key genes associated with adipocyte maturation, such as PPARγ and C/EBP α [45], thereby arresting cells at an immature preadipocyte-like stage [46, 47]. It activates pro proliferation and pro survival signaling by upregulating cyclins, such as Cyclin D1 and Cyclin D2, growth factors, such as IGF2 [48], and anti-apoptotic proteins, such as BCL2 [49], conferring a growth advantage [50]. The fusion protein can also interfere with DNA damage repair mechanisms, promoting genomic instability. Round cell transition, low-grade MLS to high-grade MLS with an increased round cell component, is a key malignant conversion process [51]. This transition typically accompanies a higher proliferative index, elevated Ki-67 index, TP53 mutation or loss, PIK3CA mutation, PTEN loss, and MYC amplification. The combined effects disrupt cell cycle checkpoints and amplify survival and proliferation signaling, driving an invasive phenotype [4, 5]. PLS typically exhibits a highly complex chromosomal karyotype without the hallmark alterations of WDLS and DDLS or MLPS and round-cell transformation [52]. Its highly malignant nature is closely linked to loss of core tumor suppressor pathways. TP53 mutation and or loss occurs at high frequency, over 60%, resulting in collapse of genome stability maintenance and DNA damage response [53]. RB1 pathway disruption is another core feature. Mechanisms include homozygous deletion at the CDKN2A locus, encoding p16INK4a and p14ARF [26], mutation or loss of RB1 itself [54], and amplification of CCND1 or CCND3, encoding cyclin D1 and D3 [55]. Together, these changes drive loss of G1 to S checkpoint control. Other frequent variants involve mutations or loss in PIK3CA, activating PI3K signaling [56], NF1, a negative regulator of RAS signaling [57], and ATRX, which contributes to telomere maintenance and genome stability [58], further intensifying genomic disorder and malignant behavior. This widespread genomic instability is considered a basis for the aggressiveness and poor prognosis of PLS (Fig. 3). Among these subtype-defining genetic alterations, the most direct connection to the UPS is observed in WDLS and DDLS, where MDM2 amplification functionally links genomic amplification to proteasome-mediated p53 turnover. In other subtypes, proteasome dependence is more likely to arise in a context-specific manner through turnover of key regulatory proteins and proteostasis stress adaptation, but direct subtype-specific evidence in LPS remains limited. Fig. 3LPS subtypes and their representative clinicopathological and molecular features. LPS comprises four major subtypes with distinct clinicopathological behaviors and representative molecular alterations. WDLS is characterized by adipocytic differentiation and recurrent 12q13–15 amplification. DDLS often arises from WDLS and shows additional alterations associated with dedifferentiation. MLS is characterized by abundant myxoid stroma, a branching vascular pattern, and DDIT3-related fusions, whereas progression to an increased round-cell component indicates higher grade. PLS is the most aggressive subtype and typically exhibits marked pleomorphism, complex karyotypes, and high metastatic potential. Abbreviations: LPS, liposarcoma; WDLS, well-differentiated liposarcoma; DDLS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; PLS, pleomorphic liposarcoma LPS subtypes and their representative clinicopathological and molecular features. LPS comprises four major subtypes with distinct clinicopathological behaviors and representative molecular alterations. WDLS is characterized by adipocytic differentiation and recurrent 12q13–15 amplification. DDLS often arises from WDLS and shows additional alterations associated with dedifferentiation. MLS is characterized by abundant myxoid stroma, a branching vascular pattern, and DDIT3-related fusions, whereas progression to an increased round-cell component indicates higher grade. PLS is the most aggressive subtype and typically exhibits marked pleomorphism, complex karyotypes, and high metastatic potential. Abbreviations: LPS, liposarcoma; WDLS, well-differentiated liposarcoma; DDLS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; PLS, pleomorphic liposarcoma Epigenetic regulatory imbalance Abnormal epigenetic mechanisms play key roles in LPS transition by profoundly reshaping gene expression programs without altering DNA sequence, particularly in maintaining undifferentiated states and promoting malignant conversion. Global hypomethylation can lead to genomic instability, such as transposon activation and chromosomal breaks, and aberrant activation of proto oncogenes [59]. Promoter hypermethylation of specific genes can silence tumor suppressors. For example, in DDLS, tumor suppressors such as RASSF1A, regulating microtubules and apoptosis, HIC1, a transcriptional repressor, and p16INK4a, CDKN2A, are often inactivated by promoter hypermethylation [60]. This epigenetic silencing can cooperate with genetic loss, such as CDKN2A deletion, to promote tumor progression and dedifferentiation [61]. In MLS, specific DNA methylation profiles have also been linked to tumor grade and clinical behavior. Increased repressive histone marks are another layer. The histone methyltransferase EZH2, the core catalytic subunit of PRC2, is often overexpressed in high grade subtypes such as DDLS [62]. EZH2 catalyzes trimethylation of histone H3 lysine 27, H3K27me3, a repressive mark [63]. Overexpression leads to broad silencing of differentiation related genes, such as HOX clusters, and tumor suppressors, strongly maintaining an undifferentiated and stem like state [64], which is essential for sustaining and evolving the dedifferentiated phenotype in DDLS. Histone acetylation imbalance also contributes. Dysregulated activity of histone acetyltransferases and histone deacetylases alters chromatin structure and transcription. Increased histone deacetylase activity is often linked to gene silencing [65]. Histone deacetylase inhibitors can reverse parts of epigenetic repression and induce differentiation or apoptosis in preclinical models [66], with activity noted particularly in DDLS. Multiple microRNAs are dysregulated across LPS subtypes and regulate proliferation, apoptosis, differentiation, and invasion and metastasis by targeting key genes [67]. For instance, in DDLS, certain microRNAs are often downregulated, and their normal function is to suppress oncogenic factors such as CDK6 and EZH2 [68]. Their loss promotes cell cycle progression and epigenetic silencing. miR-155 is often highly expressed in MLS and can target tumor suppressors such as SOCS1, a negative regulator of JAK-STAT signaling, thereby promoting proliferation [69, 70]. Other microRNA clusters, such as miR-143 and miR-145, which participate in differentiation regulation, are also frequently downregulated in LPS [71]. Long non coding RNAs, such as TODL, associated with metastasis, and HOTAIR, which recruits PRC2 to silence genes, have been reported in multiple cancers to participate in metastasis and prognosis [72]. Their dysregulation in LPS, especially in high grade subtypes, and their roles in promoting transition, such as epithelial to mesenchymal transition and stemness maintenance, are under active investigation. These epigenetic programs may also shape proteasome-associated vulnerability by altering dependence on protein turnover, stress adaptation, and differentiation blockade, thereby providing a rationale for combination strategies rather than implying a uniform UPS-driven mechanism across all LPS subtypes. Dysregulation of key signaling pathways Multiple intracellular signaling pathways are constitutively or persistently activated in LPS and provide sustained oncogenic signals that support growth, survival, blocked differentiation, and malignant transition. PI3K-AKT-mTOR signaling is among the most frequently activated core survival and proliferative pathways in LPS, especially in DDLS, high-grade MLS with an increased round cell component, and PLS, and is an important driver of malignant transition [56, 73]. Activation occurs via diverse mechanisms. Receptor tyrosine kinase activation includes overexpression of IGF-1R, PDGFR alpha and β, and EGFR, or overexpression of their ligands, such as IGF2 in MLS, resulting in sustained signaling input [48, 74, 75, 76]. PTEN loss or inactivation, via deletion, mutation, or epigenetic silencing, removes a key negative regulator and results in persistent AKT activation [77]. Activation of this pathway promotes cell growth, metabolic reprogramming including enhanced glycolysis, inhibition of apoptosis, and angiogenesis, and is strongly associated with chemotherapy resistance. Higher activation often correlates with high grade disease and poor prognosis. The RAS–RAF–MEK–ERK cascade, also known as MAPK signaling, can be activated by upstream receptor tyrosine kinases and primarily promotes proliferation and invasion. Although KRAS, NRAS, and BRAF mutations are relatively uncommon in LPS, aberrant signals from upstream receptors such as EGFR and FGFR or downstream changes such as elevated phosphorylated ERK can activate this pathway [11]. In particular, subtypes or during transition processes, such as DDLS progression, this pathway may cooperate with PI3K signaling. In MLS, the FUS::DDIT3fusion protein can directly or indirectly activate JAK-STAT signaling, especially STAT3. Activated STAT3 dimerizes, translocates to the nucleus, and regulates expression of genes that promote proliferation, such as Cyclin D1, survival, such as BCL2 and MCL1, angiogenesis, such as VEGF, and immune modulation, functioning as a key pathway for MLS and for cell survival and proliferation during round-cell transformation [78]. This pathway may also be activated in other subtypes, such as DDLS, through cytokines including IL-6 [79]. Wnt and β-catenin signaling play a key regulatory role in normal adipogenesis. Abnormalities, such as APC inactivation, CTNNB1 alterations, or nuclear accumulation of β catenin, may block adipocytic differentiation and facilitate tumor initiation. In DDLS, increased expression of Wnt pathway related genes, such as WNT5A, or nuclear β-catenin accumulation has been reported and may contribute to maintaining an undifferentiated state and promoting invasion [80]. Notch signaling participates in cell fate decisions, stemness maintenance, and differentiation control. In DDLS, elevated expression of Notch pathway genes, including ligand JAG1 and effector HES1, has been observed. Notch activation may suppress adipocytic differentiation and promote undifferentiated programs and stemness maintenance, supporting the aggressiveness and sustained growth of DDLS [81–83] (Fig. 4). Importantly, several of these signaling pathways intersect with the UPS through regulation of protein stability, stress signaling, and cell-cycle control, suggesting that proteasome targeting is best understood as a complementary vulnerability embedded within broader subtype-specific signaling networks. Fig. 4Key mechanisms driving LPS malignancy. This figure summarizes the major processes implicated in LPS progression, including subtype-associated genetic alterations, aberrant signaling pathways, epigenetic dysregulation, tumor microenvironment remodeling, and immune evasion, and highlights that malignant progression is driven by the convergence of cell-intrinsic molecular alterations and tumor-microenvironmental cues. Abbreviations: LPS, liposarcoma; TME, tumor microenvironment; TAMs, tumor-associated macrophages; CAFs, cancer-associated fibroblasts; ECM, extracellular matrix Key mechanisms driving LPS malignancy. This figure summarizes the major processes implicated in LPS progression, including subtype-associated genetic alterations, aberrant signaling pathways, epigenetic dysregulation, tumor microenvironment remodeling, and immune evasion, and highlights that malignant progression is driven by the convergence of cell-intrinsic molecular alterations and tumor-microenvironmental cues. Abbreviations: LPS, liposarcoma; TME, tumor microenvironment; TAMs, tumor-associated macrophages; CAFs, cancer-associated fibroblasts; ECM, extracellular matrix Roles of the tumor microenvironment Tumors are not isolated cell masses. The tumor microenvironment (TME), is a complex ecosystem comprising multiple cell types, extracellular matrix components, signaling molecules, and physicochemical features such as hypoxia. The TME plays active and indispensable roles in malignant transition, invasion, and metastasis of LPS [84]. Tumor-associated macrophages (TAMs), particularly the M2-polarized subset with immunosuppressive and pro-tumorigenic properties, are prominently enriched in liposarcoma, especially in high-grade subtypes such as DDLS and PLS. These cells secrete a broad spectrum of cytokines including IL-6, IL-10, and TGF-β, growth factors including EGF, PDGF, and VEGF, as well as proteolytic enzymes including matrix metalloproteinases. Through these mediators, TAMs exert multiple tumor-promoting effects: they directly enhance tumor-cell proliferation, survival, migration, and invasion; stimulate angiogenesis and lymphangiogenesis; and remodel the extracellular matrix, thereby creating a permissive microenvironment for local invasion and metastatic dissemination [85], and establishing an immunosuppressive environment by secreting IL-10 and TGF-β, expressing immune checkpoint ligands such as PD-L1, and recruiting regulatory T cells [86]. Cytotoxic T lymphocyte infiltration is generally associated with better outcomes and indicates potential antitumor immune responses. However, LPS, particularly DDLS, often exhibits low immunogenicity and an immunosuppressive, immune cold microenvironment. Tumor cells and TAMs may express PD-L1 and suppress cytotoxic T cell function through checkpoint signaling. Regulatory T cell infiltration further reinforces immunosuppression and is an important factor for immune escape and tumor progression [87, 88]. Activated fibroblasts, commonly referred to as cancer associated fibroblasts, abbreviated as CAFs, are major stromal components [89]. CAFs promote malignant transition and invasion in LPS through several mechanisms. First, they secrete large amounts of collagen, fibronectin, hyaluronan, and other extracellular matrix components, increasing matrix stiffness and tension. This altered physical microenvironment forms a barrier and activates integrin dependent signaling in tumor cells, triggering pathways such as FAK-SRC, PI3K-AKT, and Hippo-YAP and TAZ. YAP and TAZ activation is considered particularly relevant in DDLS progression [90]. Second, CAFs secrete pro tumor factors. CAF derived growth factors, such as HGF and SDF-1, also known as CXCL12, cytokines such as IL-6, and proteases, such as MMPs, directly stimulate tumor proliferation, survival, migration, invasion, and stemness maintenance. HGF activation of c-MET is a key pro invasive signal [91]. SDF-1 and CXCL12 participate in metastatic seeding through CXCR4 [92, 93]. Third, extracellular matrix remodeling is amplified. Tumor cells and stromal cells produce intense remodeling with overexpression of degradation enzymes such as MMPs and ADAM family metalloproteinases, degrading basement membranes and extracellular matrix to facilitate invasion [94]. Meanwhile, abnormal and highly cross- linked extracellular matrix, such as thickened and aligned collagen fibers, accumulates and leads to desmoplasia [95]. As noted, stiff matrix not only provides support but also persistently activates mechanotransduction programs through integrin focal adhesion kinase signaling and Hippo-YAP and TAZ signaling, driving malignant transition, local invasion, and treatment resistance. Rapidly growing tumors require new vasculature. Tumor cells and TAMs in LPS, particularly in high grade subtypes such as DDLS, PLS, and high-grade MLS with an increased round cell component, secrete VEGF, FGF, and PDGF to induce angiogenesis [96, 97]. However, neovessels are often disorganized and dysfunctional, resulting in microenvironmental hypoxia. Hypoxia selects for more invasive and anti apoptotic clones and activates HIF-1α signaling, inducing genes that promote metastasis, angiogenesis, and metabolic reprogramming [98–101]. Hypoxia is therefore a major microenvironmental pressure that drives further malignant evolution and distant metastasis (Table 1). In addition, microenvironmental stressors such as hypoxia, inflammatory cytokines, and therapy-induced proteotoxic stress may modify tumor dependence on proteasome function and could partly influence the response to proteasome-based combination strategies. Table 1Key molecular mechanisms driving liposarcoma progressionCategoryKey factorsMechanismBiological effectsRef.Epigenetic dysregulationDNA methylation (RASSF1A,HIC1, CDKN2A)Promoter hypermethylation leads to transcriptional silencing of tumor suppressor genesPromotes tumor progression and dedifferentiation [59–61]EZH2 / H3K27me3EZH2 mediates histone H3K27 trimethylation, repressing differentiation-related genesMaintains undifferentiated phenotype and tumor stemness [62–64]HDACsHistone deacetylation alters chromatin structure and gene transcriptionGene silencing and tumor progression [65, 66]Non-coding RNAsmiRNAs(miR-155, miR-143/145)Dysregulated miRNAs regulate oncogenes or tumor suppressor genesControl proliferation, apoptosis, and differentiation [67–71]lncRNAs(HOTAIR, TODL)Recruitment of chromatin-modifying complexes such as PRC2Promote metastasis and EMT [72]Signaling pathwaysPI3K–AKT–mTORRTK activation, PIK3CA mutation, or PTEN lossPromotes proliferation, metabolism, and survival [48, 56, 73– 77]RAS–RAF–MEK–ERK (MAPK)Activated by upstream RTK signalingEnhances tumor proliferation and invasion [11]JAK–STATActivated by FUS-DDIT3 or cytokines such as IL-6Regulates tumor growth and immune responses [78, 79]Wnt/β-cateninAPC inactivation or CTNNB1 activationBlocks adipocyte differentiation and promotes tumor initiation [80]Notch signalingActivation of JAG1–HES1 signaling axisMaintains stemness and inhibits differentiation [81–83]Tumor microenvironmentTAMsSecretion of cytokines (IL-6, IL-10, TGF-β) and growth factors (VEGF, PDGF)Immunosuppression and angiogenesis [85, 86]CAFsECM remodeling and secretion of HGF, CXCL12, and MMPsPromotes invasion and metastasis [89–93]HypoxiaActivation of HIF-1α signalingAngiogenesis and metabolic reprogramming [96–101] Table 1Key molecular mechanisms driving liposarcoma progressionCategoryKey factorsMechanismBiological effectsRef.Epigenetic dysregulationDNA methylation (RASSF1A,HIC1, CDKN2A)Promoter hypermethylation leads to transcriptional silencing of tumor suppressor genesPromotes tumor progression and dedifferentiation [59–61]EZH2 / H3K27me3EZH2 mediates histone H3K27 trimethylation, repressing differentiation-related genesMaintains undifferentiated phenotype and tumor stemness [62–64]HDACsHistone deacetylation alters chromatin structure and gene transcriptionGene silencing and tumor progression [65, 66]Non-coding RNAsmiRNAs(miR-155, miR-143/145)Dysregulated miRNAs regulate oncogenes or tumor suppressor genesControl proliferation, apoptosis, and differentiation [67–71]lncRNAs(HOTAIR, TODL)Recruitment of chromatin-modifying complexes such as PRC2Promote metastasis and EMT [72]Signaling pathwaysPI3K–AKT–mTORRTK activation, PIK3CA mutation, or PTEN lossPromotes proliferation, metabolism, and survival [48, 56, 73– 77]RAS–RAF–MEK–ERK (MAPK)Activated by upstream RTK signalingEnhances tumor proliferation and invasion [11]JAK–STATActivated by FUS-DDIT3 or cytokines such as IL-6Regulates tumor growth and immune responses [78, 79]Wnt/β-cateninAPC inactivation or CTNNB1 activationBlocks adipocyte differentiation and promotes tumor initiation [80]Notch signalingActivation of JAG1–HES1 signaling axisMaintains stemness and inhibits differentiation [81–83]Tumor microenvironmentTAMsSecretion of cytokines (IL-6, IL-10, TGF-β) and growth factors (VEGF, PDGF)Immunosuppression and angiogenesis [85, 86]CAFsECM remodeling and secretion of HGF, CXCL12, and MMPsPromotes invasion and metastasis [89–93]HypoxiaActivation of HIF-1α signalingAngiogenesis and metabolic reprogramming [96–101] Key molecular mechanisms driving liposarcoma progression DNA methylation (RASSF1A, HIC1, CDKN2A) miRNAs (miR-155, miR-143/145) lncRNAs (HOTAIR, TODL) Roles of proteasome components in liposarcoma The proteasome is a large multisubunit protein complex responsible for targeted degradation of most intracellular proteins, especially misfolded, damaged, or short lived regulatory proteins. This process is primarily mediated by the ubiquitin proteasome system, and is essential for maintaining cellular homeostasis and regulating key biological processes such as cell cycle progression, DNA damage repair, signal transduction, apoptosis, and differentiation [102, 103]. In LPS, particularly in specific subtypes such as WDLS/DDLS, proteasome function and its regulatory mechanisms profoundly influence tumor cell survival, proliferation, and the maintenance of malignant phenotypes, and may serve as both important therapeutic targets and central regulators of proteostasis. The central mechanism underlying this role is closely associated with a hallmark molecular event in WDLS/DDLS, namely amplification of the 12q13–15 chromosomal region leading to overexpression of the MDM2 oncogene. MDM2, an E3 ubiquitin ligase, serves as the principal negative regulator of the tumor suppressor protein p53. In normal cells, MDM2 ubiquitinates p53, thereby marking it for recognition and degradation by the 26 S proteasome. Through this process, cellular levels and activity of p53 are tightly controlled, preventing excessive activation that would otherwise lead to cell cycle arrest or apoptosis [104, 105]. However, in WDLS and DDLS, amplification and overexpression of MDM2 markedly strengthen this negative feedback, leading to excessive proteasome-mediated degradation of functional p53 and functional p53 inactivation, even if TP53 is not mutated. Loss of p53 function allows cells to evade DNA damage induced apoptosis and senescence, gain sustained proliferative capacity, and accumulate genomic instability. This is a core driver of WDLS initiation and one of the key forces promoting transition toward the more invasive DDLS phenotype. Therefore, inhibiting proteasome activity is a key strategy to reverse MDM2 mediated p53 degradation and to reactivate p53 signaling, inducing apoptosis or growth arrest. Preclinical studies indicate that proteasome inhibitors, such as Bortezomib and Carfilzomib, can effectively suppress proliferation and induce apoptosis in WDLS and DDLS models. Mechanistically [106–108]. They block proteasome degradation of p53, leading to p53 accumulation and restored transcriptional activity, and activate downstream pro-apoptotic genes, such as BAX and PUMA, and cell cycle inhibitors, such as p21 [109]. Importantly, proteasome inhibition may be influenced by subtype and molecular background. In WDLS and DDLS with wild type TP53, efficacy may be more pronounced, whereas in TP53 mutant DDLS or in PLS, where p53 signaling is already disrupted, the effect may be limited [21]. Accordingly, direct mechanistic support is currently strongest for the MDM2-p53-proteasome axis in WDLS and DDLS. In MLS, although the core driver is FUS::DDIT3, the proteasome also participates in regulating stability of this fusion protein and turnover of downstream effectors [110]. Some studies suggest that Bortezomib can induce apoptosis in MLS cells, potentially through activation of endoplasmic reticulum stress due to misfolded protein accumulation, suppression of pro survival pathways such as NF-κB, or activation of p53 independent apoptosis pathways [111]. However, these findings remain limited and do not yet establish a proteasome-centered mechanism in MLS. PLS often shows high genomic instability and frequent TP53 mutation, and survival may depend more heavily on sustained protein synthesis and efficient clearance of misfolded proteins; however, its potential sensitivity to proteasome inhibition remains largely hypothetical because direct LPS-specific evidence is still limited. Beyond direct tumor cell killing, proteasome inhibitors may also indirectly affect the tumor microenvironment, such as suppressing production of pro-inflammatory and pro-angiogenic factors or influencing immune cell activity [112], although these effects remain insufficiently validated in liposarcoma. Despite encouraging preclinical data supporting proteasome inhibition in LPS, especially in WDLS and DDLS, these findings have not yet translated into clinically validated proteasome-targeted therapy for LPS. In solid tumors, including liposarcoma, proteasome inhibitors have thus far shown limited clinical efficacy, and single-agent activity in advanced sarcoma has been minimal. This likely reflects several converging barriers, including inadequate intratumoral drug delivery, protective effects of the tumor microenvironment, adaptive resistance mechanisms such as compensatory autophagy and proteasome subunit remodeling, and dose-limiting toxicities, including peripheral neuropathy and myelosuppression. Accordingly, ongoing efforts are focused on evaluating more selective next-generation proteasome inhibitors and rational combination strategies with CDK4/6 inhibitors, MDM2 antagonists, chemotherapy, or radiotherapy. At present, however, these approaches should be regarded as investigational translational strategies rather than clinically established therapeutic options in LPS. Candidate stratification variables, including histologic subtype, MDM2 amplification status, TP53 integrity, CDKN2A/RB pathway status, proteasome component expression or activity, and the degree of proteostasis stress or tumor microenvironmental immunosuppression, may help guide future preclinical refinement and early-phase clinical evaluation, but their predictive value in LPS remains to be established. Overall, the proteasome remains a biologically important and therapeutically relevant investigational node in LPS, particularly in MDM2-overexpressing WDLS and DDLS, but further LPS-specific translational and clinical validation is still required (Fig. 5). Fig. 5Representative therapeutic strategies and their mechanistic basis in liposarcoma. Schematic illustration of major targeted and immune-based therapeutic approaches in liposarcoma. MDM2 antagonists restore p53 activity by disrupting the MDM2–p53 interaction, thereby reactivating tumor suppressor signaling and inhibiting tumor cell proliferation. CDK4 inhibitors block CDK4/Cyclin D–mediated Rb phosphorylation, suppress the G1-to-S transition, and induce G1-phase cell-cycle arrest. PPARγ agonists promote terminal adipocytic differentiation and reduce tumor cell proliferation by shifting liposarcoma cells toward a more differentiated state. In parallel, tumor vaccines and PD-L1 inhibitors enhance antitumor immune responses, activate effector T-cell activity, and attenuate immune evasion within the tumor microenvironment. Collectively, these strategies target complementary vulnerabilities in p53 suppression, cell-cycle dysregulation, differentiation blockade, and immune evasion in liposarcoma. Abbreviations: MDM2, murine double minute 2; CDK4, cyclin-dependent kinase 4; Rb, retinoblastoma protein; PPARγ, peroxisome proliferator-activated receptor gamma; PD-L1, programmed death-ligand 1 Representative therapeutic strategies and their mechanistic basis in liposarcoma. Schematic illustration of major targeted and immune-based therapeutic approaches in liposarcoma. MDM2 antagonists restore p53 activity by disrupting the MDM2–p53 interaction, thereby reactivating tumor suppressor signaling and inhibiting tumor cell proliferation. CDK4 inhibitors block CDK4/Cyclin D–mediated Rb phosphorylation, suppress the G1-to-S transition, and induce G1-phase cell-cycle arrest. PPARγ agonists promote terminal adipocytic differentiation and reduce tumor cell proliferation by shifting liposarcoma cells toward a more differentiated state. In parallel, tumor vaccines and PD-L1 inhibitors enhance antitumor immune responses, activate effector T-cell activity, and attenuate immune evasion within the tumor microenvironment. Collectively, these strategies target complementary vulnerabilities in p53 suppression, cell-cycle dysregulation, differentiation blockade, and immune evasion in liposarcoma. Abbreviations: MDM2, murine double minute 2; CDK4, cyclin-dependent kinase 4; Rb, retinoblastoma protein; PPARγ, peroxisome proliferator-activated receptor gamma; PD-L1, programmed death-ligand 1 Advances in proteasome targeting for cancer therapy The proteasome, as the core executor of the UPS, is a large multisubunit complex [102]. Its catalytic core is the 20 S core particle, capped by 19 S regulatory particles to form the 26 S proteasome, which recognizes, unfolds, and degrades polyubiquitin tagged proteins. The 20 S core contains four stacked heptameric rings arranged as alpha 7, β seven, β seven, alpha 7. Proteolytic activity resides in β subunits: β 1 with caspase like activity, β 2 with trypsin like activity, and β5 with chymotrypsin like activity, with β5 often being the most dominant [113]. A specialized form, the immunoproteasome, can be induced by inflammatory cytokines such as interferon gamma, and replaces constitutive β subunits with inducible homologs LMP2, also known as i β1, MECL-1, also known as i β2, and LMP7, also known as i β5. The immunoproteasome plays unique roles in antigen processing and presentation, regulation of inflammatory cytokine production, such as through IκB degradation and NF-κB activation, and responses to oxidative stress [114]. Cancer cells often depend heavily on efficient proteasome function to clear misfolded or damaged proteins, maintain oncogenic signaling, such as through degradation of tumor suppressors like p53 and p27, and resist apoptotic pressure, due to rapid proliferation, metabolic stress, genomic instability, and accumulation of oncoproteins [115, 116]. Therefore, targeting the proteasome, especially catalytic subunits, is an attractive anticancer strategy. Inhibition leads to accumulation of abnormal proteins and pro apoptotic factors, such as NOXA, BAX, and p53, triggers endoplasmic reticulum stress and the unfolded protein response, induces cell cycle arrest, such as through stabilization of p21 and p27, and ultimately promotes apoptosis. Proteasome inhibitors, abbreviated as PIs, were developed based on this rationale. Since 2003, when Bortezomib became the first PI approved by the FDA for relapsed or refractory multiple myeloma [117], proteasome targeting has advanced substantially and expanded into other hematologic malignancies and selected solid tumors. Bortezomib is a reversible inhibitor whose boronic acid moiety forms a covalent but reversible interaction with the threonine residue in the β 5 active site, and also partially inhibits β 1 activity [118]. It significantly improved survival in multiple myeloma and became a cornerstone therapy. However, Bortezomib has dose limiting toxicities, such as peripheral neuropathy and thrombocytopenia, and resistance issues [119]. This led to the development of second generation PIs to improve efficacy, reduce toxicity, and overcome resistance. Carfilzomib is a representative irreversible PI. Its epoxyketone warhead forms an irreversible covalent bond with the β 5 threonine residue, providing higher selectivity and more potent and durable β 5 inhibition [120]. Carfilzomib shows significant efficacy in patients with Bortezomib resistant or relapsed multiple myeloma, and the risk of peripheral neuropathy is lower, making it an important option [121, 122]. Ixazomib is the first oral PI and is a reversible β 5 inhibitor with convenient administration for maintenance strategies [123]. Marizomib is a natural product derived irreversible PI from marine bacteria. It can penetrate the blood brain barrier and potently inhibits all three proteasome activities, β 5, β 1, and β 2, including immunoproteasome subunits LMP7, LMP2, and MECL-1. This feature suggests potential in central nervous system tumors such as glioblastoma and in certain hematologic malignancies, and clinical trials are ongoing [124, 125]. Beyond hematologic malignancies, proteasome inhibitors face challenges in solid tumors, but progress continues. In LPS, particularly WDLS and DDLS, the hallmark MDM2 amplification causes MDM2 overexpression and excessive proteasome mediated p53 degradation, and preclinical studies indicate that Bortezomib and related PIs can inhibit proteasome activity, stabilize p53, and induce apoptosis, providing a potential targeted strategy. In addition, immunoproteasome targeting inhibitors, such as ONX 0914 and agents selectively inhibiting LMP7, are emerging. These agents aim not only to enhance antitumor immunity by altering antigen peptide repertoires, promoting immunogenic cell death, and suppressing immunosuppressive cytokine production, but also to overcome resistance in certain tumors. Their potential as monotherapy or in combination with immune checkpoint blockade, such as anti PD-1 therapy, is being actively evaluated. Despite milestone successes in multiple myeloma, broad application of PIs faces major bottlenecks. Resistance mechanisms include mutations in proteasome β subunits, especially β 5, leading to reduced drug binding, increased expression of proteasome subunits or assembly [126], activation of alternative protein degradation pathways such as autophagy lysosome systems [127], enhanced drug efflux pumps such as P-glycoprotein [128], and increased reliance on anti-apoptotic proteins such as MCL-1 [129]. Toxicity is another constraint. Beyond Bortezomib associated peripheral neuropathy and thrombocytopenia, newer PIs have distinct toxicity profiles, such as Carfilzomib related cardiovascular toxicity [130], Ixazomib related gastrointestinal events and rash [131], and Marizomib related neuropsychiatric adverse effects [125]. Limited efficacy in solid tumors is another challenge, involving delivery barriers, microenvironmental protection, compensatory degradation pathways, and biological differences in proteasome dependence between solid and hematologic tumors [132]. To address these challenges, current efforts focus on several directions. First is developing newer, more selective PIs, such as inhibitors that selectively target immunoproteasome subunits LMP7, LMP2, and MECL-1, aiming to enhance antitumor immune activity and reduce toxicity linked to inhibition of constitutive proteasomes, and developing formulations that better penetrate solid tumor barriers, such as nanoparticle delivery. Second is mechanism guided combinations to enhance efficacy and overcome resistance. Examples include combining with immunotherapy, such as PD-1 and PD-L1 antibodies and CAR-T cells. PIs may induce immunogenic cell death, enhance antigen presentation, and improve immunosuppressive microenvironments, such as reducing regulatory T cells and suppressing MDSC function and decreasing IL-6, thereby potentially converting immune cold tumors into immune hot tumors and improving response rates. Combining with epigenetic drugs, such as histone deacetylase inhibitors, including Vorinostat and Panobinostat, may produce synergy through coordinated endoplasmic reticulum stress and unfolded protein response induction and by blocking the aggresome pathway as a compensatory route for proteasome inhibition, showing promise in multiple myeloma and lymphoma and under exploration in solid tumors including sarcoma [133]. Combining with targeted therapies is another key approach. In MDM2 amplified tumors, such as WDLS and DDLS, combining a PI with an MDM2 antagonist, such as Milademetan, may more completely restore p53 function [134]. Or in combination with CDK4/6 inhibitors, such as palbociclib, to achieve synergistic cell-cycle blockade, or with conventional chemotherapy and radiotherapy to exploit the chemosensitizing and radiosensitizing effects of proteasome inhibitors [135]. Third is exploring strategies targeting other UPS components, such as inhibiting or degrading pathogenic E3 ligases, such as targeting MDM2 and IAPs, and targeting deubiquitinases, and using PROTAC technology to achieve more precise degradation of disease driving proteins. Overall, the proteasome is a key intracellular protein degradation hub, and its inhibitors represent important anticancer agents, particularly in hematologic malignancies. With deeper understanding of proteasome and immunoproteasome biology, development of more selective inhibitors, and optimization of mechanism guided combination strategies, proteasome family targeting may help overcome current limitations and bring therapeutic benefits to broader tumor types, including refractory solid tumors (Fig. 6). Fig. 6Role of proteasome inhibitors in cancer therapy. PIs target the catalytic β5 subunit of the 20 S proteasome to block proteasome-mediated protein degradation. Representative agents include reversible and irreversible inhibitors such as Bortezomib and Carfilzomib. Inhibition of proteasome activity leads to accumulation of misfolded or damaged proteins, induction of endoplasmic reticulum (ER) stress, suppression of NF-κB signaling, and activation of apoptotic pathways, ultimately reducing tumor burden and inhibiting tumor growth. Resistance mechanisms may arise through proteasome subunit mutations, ubiquitination alterations, autophagy activation, and tumor microenvironment–mediated protection. Collectively, the key mechanistic message is that proteasome inhibition suppresses tumor growth by inducing proteotoxic stress and apoptosis, whereas adaptive resistance may limit therapeutic efficacy. Abbreviations: PIs, proteasome inhibitors; ER, endoplasmic reticulum; NF-κB, nuclear factor kappa B Role of proteasome inhibitors in cancer therapy. PIs target the catalytic β5 subunit of the 20 S proteasome to block proteasome-mediated protein degradation. Representative agents include reversible and irreversible inhibitors such as Bortezomib and Carfilzomib. Inhibition of proteasome activity leads to accumulation of misfolded or damaged proteins, induction of endoplasmic reticulum (ER) stress, suppression of NF-κB signaling, and activation of apoptotic pathways, ultimately reducing tumor burden and inhibiting tumor growth. Resistance mechanisms may arise through proteasome subunit mutations, ubiquitination alterations, autophagy activation, and tumor microenvironment–mediated protection. Collectively, the key mechanistic message is that proteasome inhibition suppresses tumor growth by inducing proteotoxic stress and apoptosis, whereas adaptive resistance may limit therapeutic efficacy. Abbreviations: PIs, proteasome inhibitors; ER, endoplasmic reticulum; NF-κB, nuclear factor kappa B Conclusion The heterogeneity of liposarcoma fundamentally arises from subtype specific genetic drivers and multilayer regulatory imbalances that accumulate over time. Dedifferentiation from WDLS to DDLS and high-grade round-cell transformation in MLS are not triggered by a single event. Rather, they are dynamic processes built on core driver alterations and shaped by additive disruptions in cell cycle control, strengthened pro survival signaling, epigenetic silencing, and tumor microenvironment remodeling. Accordingly, any strategy that attempts to treat all subtypes with a single universal approach is likely to face divergent real world efficacy. Precision subtyping and stratified interventions are prerequisites for improving the upper bound of treatment benefit. Within this evolutionary framework, the ubiquitin proteasome system provides a pivotal hub with both mechanistic explanatory power and therapeutic tractability. In MDM2 amplified WDLS and DDLS, proteasome mediated excessive degradation of p53 constitutes a key pathway sustaining tumor survival and promoting transition, establishing a direct logic for proteasome inhibition to restore tumor suppressor signaling and induce apoptosis or durable growth arrest. At the same time, antitumor effects of proteasome inhibition show strong dependence on molecular context. Integrity of the TP53 axis, the status of UPS components, and the degree of reliance on proteostasis stress buffering likely define sensitivity boundaries. This helps explain the inconsistent efficacy of PIs in solid tumors and the constraints imposed by tolerable dosing. For translational applications, future work should prioritize biomarker-guided preclinical stratification and rational combination testing rather than assuming near-term clinical implementation of proteasome-targeted therapy in LPS. A practical next step will be to evaluate mechanism-driven combinations around the MDM2-p53 axis, CDK4/6 checkpoints, PI3K-AKT-mTOR signaling, and epigenetic maintenance programs in subtype-informed models and early-phase clinical studies. Ultimately, the proteasome is best viewed at present as a promising translational target that links subtype drivers, proteostasis stress, and treatment response, but its therapeutic value in LPS still requires stronger LPS-specific clinical validation.